
ATAI Stock Forecast & Price Target
ATAI Analyst Ratings
Bulls say
AtaiBeckley is on track to revolutionize mental health treatments with its innovative pipeline, including BPL-003, VLS-01, and EMP-01, which are in Phase 2 development for TRD and social anxiety disorder. Recent acquisition by Eli Lilly, a major pharmaceutical company, solidifies the company's promising outlook, with a cash upfront price of $6.75 per share, plus a contingent value right of up to $2.50 per share tied to development and regulatory milestones. These milestones add potential additional value of up to $1 billion, making the total deal worth approximately $3.8 billion, a significant premium to AtaiBeckley's 30-day volume-weighted average trading price.
Bears say
AtaiBeckley is heavily reliant on BPL-003, a mebufotenin benzoate nasal spray for treatment-resistant depression (TRD), which is currently in Phase 3 clinical development and expected to drive over $2 billion in sales by 2035 with a 60% probability of success. However, there is potential competition from Spravato, and AtaiBeckley's transformation to a fully owned asset model will be crucial in driving shareholder value. Their financial success will heavily depend on the success and market adoption of BPL-003.
This aggregate rating is based on analysts' research of Atai Life Sciences BV and is not a guaranteed prediction by Public.com or investment advice.
ATAI Analyst Forecast & Price Prediction
Start investing in ATAI
Order type
Buy in
Order amount
Est. shares
0 shares